Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)
Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in Relapsing and refractory systemic lupus erythematosus
Phase:
NA
Details
Lead Sponsor:
Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborator:
The First Affiliated Hospital of University of Science and Technology of China